1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
MGI Tech Co., Ltd. Class A

MGI Tech Co., Ltd. Class A

SSSE:688114
62.52
CNY
+0.16
(+0.26%)
21.28BMarket Cap
Oct 24Next Earn
MGI Tech Co., Ltd. Class A
SSE:688114
(Shanghai Stock Exchange)

Recent

price

62.52

P/E

ratio

- -

div

yld

0.07%

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.94
2.66
2.64
7.57
10.56
10.98
7
7.32
6.76
- -
Revenue per Share
-0.1
0.3
-0.59
0.71
1.3
5.26
-1.46
-1.46
-0.54
- -
Basic EPS, GAAP
-0.02
1.46
-0.98
-1.34
2.03
1.25
-3.91
-2.82
0.06
- -
Free Cash Flow per Basic Share
0.03
0.01
0.16
0.21
0.04
- -
0.37
0.06
0.05
0.04
Dividend per Share
1.49
-6.13
-4.17
9.36
10.78
22.72
20.77
18.94
18.36
16.9
Book Value per Share
0.77
-7.7
-6.36
7.39
9.03
21.06
19.19
17.44
16.94
15.34
Tangible Book Value per Share
413
413
413
367
372
385
416
412
411
410
Basic Weighted Avg Shares
802
1,097
1,091
2,780
3,929
4,231
2,911
3,013
2,780
- -
Sales/Revenue/Turnover
-8.19
8.13
-4.24
13.15
20.34
7.03
-15.91
-12.52
-5.89
- -
Operating Margin (%)
44
70
103
149
213
263
312
420
408
- -
Depreciation Expense
-42
125
-244
261
484
2,026
-607
-601
-222
- -
Net Income, GAAP
- -
- -
- -
7.94
20.19
20.08
- -
- -
- -
- -
Effective Tax Rate (%)
-5.2
11.35
-22.34
9.38
12.31
47.9
-20.87
-19.94
-7.99
- -
Profit Margin (%)
130
-2,956
-2,550
2,340
2,592
7,115
5,512
4,919
4,854
4,615
Working Capital
- -
8
4
102
92
78
260
683
825
1,185
LT Debt
564
-2,233
-1,499
3,544
4,075
9,453
8,674
7,892
7,651
7,042
Total Equity
- -
- -
- -
13.91
12.42
3.33
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
16.54
11.74
29.4
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
12.92
30.2
-6.73
-7.27
-2.86
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
179
209
95
LT Borrowings
629
810
996
LT Finance Leases
195
185
188
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
417
417
417
Market Capitalization
25,308
20,484
21,276

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,448
6,216
6,083
Cash, Cash Equivalents & STI
3,722
3,582
3,581
Accounts Receivable, Net
1,401
1,244
1,191
Inventories
1,039
1,100
1,024
Total Current Liabilities
1,594
1,632
1,468
Payables & Accruals
- -
- -
- -
ST Debt
179
209
95
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.33%
-3.05%
Free Cash Flow
- -
-171.52%
-102.11%
Net Income, GAAP
- -
42.06%
-63.03%
Sales/Revenue/Turnover
- -
2.71%
-7.73%
Total Cash Common Dividend
- -
12,099.52%
-18.01%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
531
678
660
1,143
3,013
2025
469
659
- -
911
2,780
2026
585
781
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.49
-0.24
-0.4
-0.34
-1.46
2025
-0.41
0.07
- -
-0.25
-0.54
2026
-0.26
-0.13
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.04
0.06
2025
0.01
0.01
- -
0.01
0.05
2026
0.01
0.02
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
MGI Tech Co., Ltd. is a China-based biotechnology and life science instrument company engaged in the research, development, manufacturing, and commercialization of genetic sequencing devices, laboratory automation equipment, and multi-omics technologies for clinical and scientific research applications. The company operates through three core business segments: Gene Sequencing, Laboratory Automation, and New Business. Its Gene Sequencing segment provides high-throughput and ultra-high-throughput genetic sequencers based on proprietary DNBSEQ DNA nanoball technology, including the DNBSEQ-T20x2, DNBSEQ-T7, DNBSEQ-G400, DNBSEQ-G99, and benchtop DNBSEQ-E25 platforms, as well as CycloneSEQ nanopore single-molecule sequencing instruments, library preparation kits, sequencing reagents, flow cells, and chemical consumables; its Laboratory Automation segment develops automated liquid handling workstations, automated nucleic acid extractors, and sample preparation systems, including the MGISP-960, MGISP-100, and MGISP-Smart 8 platforms, alongside automated ultra-low temperature biobank sample storage systems; and its New Business segment offers single-cell sequencing library preparation systems, spatial transcriptomics platforms, remote robotic tele-ultrasound systems such as the MGIUS-R3, and bioinformatics analysis software and hardware accelerators including MegaBOLT and Zsmart laboratory management suites. The company serves genomic research institutions, clinical diagnostic laboratories, hospitals, pharmaceutical companies, disease control centers, and agricultural breeding organizations across the Asia-Pacific, Europe, North America, the Middle East, Africa, and Latin America. Founded in 2016 and spun off from BGI Group, MGI Tech Co., Ltd. is headquartered in Shenzhen, China. In recent developments, the company has expanded its global commercial footprint across international markets, opened new Customer Experience Centers and regional hubs in Europe, the Americas, and the Asia-Pacific region, rolled out the ultra-high-throughput DNBSEQ-T20x2 platform designed to lower human whole-genome sequencing costs below the one-hundred-dollar threshold, launched the CycloneSEQ nanopore sequencing series to expand into long-read sequencing, and entered into multiple global strategic partnerships with international genomics service providers, healthcare networks, and academic research institutions to advance spatial multi-omics and high-throughput clinical diagnostics.